Being the first to file, Ranbaxy will enjoy 180-day exclusivity for pravastatin 80mg. According to the company, the annual sales for the heart drug are $209 million.
Pravastatin is indicated in the treatment of primary prevention of several types of coronary diseases, and is the therapeutic equivalent to the reference listed drug Pravachol, which is marketed by Bristol-Myers Squibb.